First Results from the Dose Escalation Part of the Phase 1 Study of KTX1001, an Oral, First-in-Class, Potent Inhibitor of MMSET/NSD2 for Relapsed/Refractory Multiple Myeloma (RRMM)

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Blood

Topics

Computer Science

Artificial Intelligence

Physics

Medicine

Cancer Oncology

Show all topics

DOI

10.1182/blood-2024-199174